US Bans BGI Group, BGI Genomics and MGI Tech Over Alleged Xinjiang Forced Labour Links

The United States has restricted shipments from Chinese biotech firms BGI Group, BGI Genomics and MGI Tech over alleged forced labour links, intensifying tensions over biotechnology and national security.

US Restricts BGI Group, BGI Genomics and MGI Tech Over Alleged Xinjiang Forced Labour Links

The United States has announced restrictions on shipments from Chinese biotechnology companies BGI Group, BGI Genomics and MGI Tech over allegations connecting them to forced labour in China's Xinjiang region. The move adds to growing tensions between Washington and Beijing over biotechnology, human rights, trade and national security.

US Blocks Shipments From Three Chinese Biotech Firms

The Trump administration has directed US Customs and Border Protection to block goods associated with BGI Group and its affiliates. The restrictions are being implemented under measures targeting products linked to alleged forced labour.

The US Department of Homeland Security (DHS) said the companies were either sourcing materials from Xinjiang or had connections to practices involving the recruitment, transportation, transfer, harbouring or receipt of forced labour from persecuted ethnic communities.

The allegations specifically concern Uyghurs and other minority groups in Xinjiang, a region in northwestern China.

BGI Group is known for its genetic sequencing technology and biotechnology research. DHS identified BGI Genomics and MGI Tech as affiliates in which BGI Group holds controlling stakes.

DHS Cites Concerns Over Genetic Testing in Xinjiang

In announcing the restrictions, DHS referred to corporate and government reporting that it described as credible information linking the companies to genetic testing activities in Xinjiang.

According to the department, collecting and analysing genetic material can facilitate surveillance and monitoring of ethnic minorities. US officials argued that such activities raise concerns about the potential use of biotechnology in repression and forced labour.

The restrictions reflect Washington's broader efforts to prevent products associated with alleged human rights violations from entering American supply chains.

BGI Group Denies Forced Labour Allegations

BGI Group rejected the accusations, stating that it had not participated in forced labour in any form. The company also expressed opposition to all forms of forced labour.

The dispute comes amid longstanding scrutiny of BGI Group by US lawmakers and policymakers. Their concerns include the company's alleged connections with the Chinese government and the potential security implications of access to large volumes of genetic information.

BGI has maintained that it is privately owned, does not serve patients in the United States and does not have access to Americans' genetic data.

US-China Competition Expands Into Biotechnology

The latest restrictions highlight how biotechnology has become an increasingly important part of the economic and technological rivalry between the United States and China.

Washington has raised concerns about the potential military, commercial and intelligence applications of advanced technologies, including genetic sequencing, artificial intelligence and supercomputing.

The US Treasury Department recently proposed additional restrictions intended to limit certain American investments in sensitive technologies in countries such as China.

The measures targeting BGI Group and its affiliates add another dimension to the dispute, placing biotechnology supply chains and human rights concerns at the centre of bilateral relations.

US Officials Have Previously Raised National Security Concerns

BGI Group, BGI Genomics and MGI Tech have faced scrutiny beyond the latest shipment restrictions. The Pentagon has designated the three companies as Chinese military companies, a classification that can create reputational challenges and increase scrutiny of their activities.

Although Congress did not pass legislation specifically banning BGI from working with federally funded medical providers, a provision adopted at the end of the previous year called for the identification of biotechnology companies considered potential security concerns.

The developments demonstrate Washington's continuing efforts to evaluate the risks associated with Chinese biotechnology firms operating in or supplying the American market.

Uyghur Forced Labour Prevention Act Forms Legal Basis

The shipment restrictions are being implemented under the Uyghur Forced Labour Prevention Act (UFLPA), which former US President Joe Biden signed into law in December 2021.

The legislation aims to prevent goods produced wholly or partly through forced labour in Xinjiang from entering the United States. It was introduced amid allegations of human rights abuses against Uyghurs and other predominantly Muslim minority groups in the region.

China has repeatedly rejected the allegations, describing them as false. Beijing has defended its policies in Xinjiang as necessary measures to combat terrorism and maintain regional stability.

In August, the Trump administration expanded the blacklist under the law by adding 43 Chinese companies, bringing the reported total to 187 entities. The policy is intended to strengthen enforcement against goods suspected of being connected to forced labour.

Upcoming Trump-Xi Meeting Adds Diplomatic Significance

The latest action comes ahead of an expected meeting between US President Donald Trump and Chinese President Xi Jinping in Shenzhen, where BGI Group is headquartered.

The leaders are seeking to maintain stability in bilateral relations amid an ongoing trade truce. Xi is also expected to travel to Florida in December for the Group of 20 leaders' summit, where another meeting with Trump could take place.

The restrictions could add to discussions about trade, technology access and economic security between the world's two largest economies.

Conclusion

The US restrictions on BGI Group, BGI Genomics and MGI Tech underscore Washington's growing scrutiny of Chinese biotechnology companies over alleged forced labour and national security risks. While BGI has denied the allegations, the action signals continued enforcement of US import restrictions and highlights the challenges facing US-China trade relations.